



June 2021

# A next generation bioscience company

Corporate Presentation



# Agenda

01

Company Overview

---

02

Diagnostics

---

03

Therapeutics

---

04

Appendix

# Company Overview

01

# Company Profile

## Diagnostics

Lead product is a **rapid point-of-care COVID-19 RT-PCR diagnostic test** launched in Europe in April 2021. Diagnostic development pipeline includes a portfolio of **real-time ultra low-cost infectious disease biosensors**.

---

## Drug Delivery

**Platform** technology to develop innovative cost-effective **transdermal and oral dissolvable formulations** of generic, hybrid-generic, and new active pharmaceutical ingredients.

---

## Drug Development

4 late-stage **neurology** therapeutics in clinical development and 2 **psychedelic** medicine programs.




Bioscience Company  
with proven therapeutics  
and innovative diagnostics  
approaching the market.

Made in Germany

# Buy and Build Strategy

XPhyto's buy and build strategy is creating a portfolio of late-stage therapeutic and diagnostic products



Two psychedelic medicine collaborations underway with leading institutions in Germany and Canada



Rapid, low-cost pathogen screening tests for pandemic and oral health applications




Experts in thin film drug delivery systems for transdermal and oral dissolvable dosage forms



Near-term focus on development and clinical validation of cannabis extract "kits" for pharmaceutical compounding in Germany



# Pipeline



■ Completed    ■ Planned

Diagnostics

02

# COVID-19 RT-PCR Diagnostic Test


Commercial Launch April 2021

- ✓ **Rapid test in 25 minutes**  
5 min hands-on time and 20 mins reaction only
- ✓ **Point-of-care diagnostic device**  
for use with minimal lab equipment
- ✓ **Low detection limit**  
diagnostic reliability of PCR tests
- ✓ **Cost-effectiveness**  
enables broad testing
- ✓ **Easily accessible**





# Diagnostic Pipeline



RAPID & Ultra rapid new medical device products

Initial launch in Europe

State funding

USD \$39.1 billion


**The global rapid test market** is projected to reach USD \$39.1 billion by 2023 with a **CAGR of 8.9 %**



Therapeutics

03

# Therapeutic Pipeline



## New formulation

Of already approved drugs

## Improvement

Of pharmacokinetics, drug compatibility, application

## Low development risk

## Initial approval and launch

In Europe

**USD \$29.2 billion**

**The global thin film drugs market** is expected to grow to USD \$29.2 billion by 2024 at a **CAGR of 10.5%.\***

# Recent Developments



## Business Highlights

Exclusive development partnership with 3a-Diagnostics GmbH  
Acquisition of Vektor Pharma TF GmbH  
Exclusive psychedelic API production partnerships

---

## Therapeutic Pipeline

Transdermal - Rotigotine TDS  
Oral Dissolvable - CBD, THC, and CBD:THC

---

## Non-dilutive Funding

Funding from German Federal Ministry of Education and Research for development of real-time ultra low-cost biosensors for high-risk pandemic threats such as influenza, swine flu and avian flu.

# Outlook



## Diagnostic Pipeline

COVID-19 PCR Test launched Q2, 2021  
Oral biosensors launch Q4, 2021

---

## Psychedelic Medicine

Exclusive development deal with Canadian University for industrial scale synthesis of pharmaceutical grade Mescaline.  
Exclusive development deal with German University for industrial scale biotech production of pharmaceutical grade Psilocybin.

# Investment Highlights

## World-class drug delivery expertise

A pipeline of novel thin-film drug delivery formulations, offering precise, efficient, optimized bioavailability

## Disruptive diagnostic pipeline

Rapid, point-of-care diagnostic and screening tests for infectious diseases and oral health indications

## Near-term market & exit opportunities

A late-stage pipeline of proprietary diagnostics and drug delivery innovations



## Efficient M&A execution

Management committed to building shareholder value through buy & build strategy

## R&D collaborations

Leveraging world-class academic expertise and state-of-the-art facilities in Germany and Canada with limited capital investment

## Unique Psychedelic Programs

First-mover advantage and industry leadership in the development of industrial scale production of pharmaceutical grade psilocybin and mescaline

# Market Overview

## > Thin film products

**Global thin film drugs market** is expected to grow to **USD \$29.2 billion** by 2024 at a CAGR of 10.5%<sup>A</sup>.

**Key players** are MonoSol Rx, Tesa Labtec GmbH, Pfizer, Inc., Novartis AG, and Wolters Kluwer, Solvay, Allergan plc. Sumitomo Dainippon Pharma Co., Ltd., IntelGenx Corp, and Transition Therapeutics, Inc<sup>B</sup>

**Disease indication:** Schizophrenia, Migraine, Opioid Dependence, Nausea & Vomiting

## > Rapid-diagnostic test

**The global rapid test market** is projected to reach **USD \$39.1 billion** by 2023 with a CAGR of 8.9%.<sup>C</sup>

Some **Key players** are ACON Laboratories, Inc., Abbott Laboratories, Artron Laboratories Inc., Alfa Scientific Designs, Inc. Becton, Dickinson and Company, BTNX, Inc., bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche AG

## > COVID-19 test

**The global COVID-19 diagnostics market** size is estimated at **USD 19.8 billion** in 2020.<sup>D</sup>

**The global COVID-19 diagnostics market** is expected to grow at a compound annual growth rate of 3.1 % from 2021 to 2027 to reach **USD 24.6 billion** by 2027.

Until today **approx. 14.5 mil** COVID-19 tests have been applied in Germany<sup>E</sup>

**Players** like QIAGEN, Quidel Corporation, Roche Holding AG, Hologic, Inc., Primerdesign Ltd., Abbott Laboratories, Cosara Diagnostics Pvt. Ltd., Thermo Fisher Scientific, AlphaBiolabs Ltd. Cepheid Inc

# Management and team



Hugh  
Rogers

LLB CEO & director

Lawyer, B.Sc

Extensive  
experience in  
venture capital



Christopher  
Ross

CPA, CFO

Accountant, B.  
Com

Experience in  
financial  
accounting,  
strategic analysis  
and consulting  
services to public  
and private  
companies



Prof. Dr. Raimar  
Löbenberg

Director

Founder and  
director of the drug  
development and  
innovation center,  
faculty of  
pharmacy and  
pharmaceutical  
science, university  
of Alberta, Canada

Co-funder of RS  
Therapeutics Inc.



Wolfgang  
Probst

Director &  
managing director

Management  
consultant  
specialized in  
investment  
consulting and  
capitalization.

Expert in mergers  
and acquisitions,  
corporate re-  
organizations, and  
divestitures.



Prof. Dr. Thomas  
Beckert

Managing director

Founder and  
managing director  
of Vektor Pharma

Experienced in  
formulation and  
machine  
development for  
thin film delivery  
systems



Prof. Dr. Wolfgang  
Eisenreich

Executive advisor

Research group  
leader  
in the department  
of chemistry, TUM

More than 20-year  
experience in  
metabolic  
pathways and  
signaling cascade  
in pathogen-host  
interaction



Manfred  
Buchberger

Head of Corp.  
Development

Expert in the  
medical and  
diagnostics  
products industry

Almost a decade of  
experience as a  
CEO and global  
management  
board member of a  
€600 Mio revenue  
diagnostics  
manufacturer.

# Contact

## XPhyto CEO

Hugh Rogers

✉ [hrogers@xphyto.com](mailto:hrogers@xphyto.com)

☎ +1 604 250 6162

---

## IR Canada & US

Knox Henderson

✉ [khenderson@xphyto.com](mailto:khenderson@xphyto.com)

☎ +1 604 551 2360

---

## EUROPE IR & PR

MC Services AG

✉ [xphyto@mc-services.eu](mailto:xphyto@mc-services.eu)

☎ +49 89 210 228 0



**Bioscience company**  
with proven therapeutics  
and innovative diagnostics  
approaching the market.

**Made in Germany**